Sweden's SciBase Q1 sees margin pressure on currency impact

SciBase Holding AB (publ)

07/05/2026 07:10

Overview

Sweden medical technology firm's Q1 net sales rose 61% yr/yr

Gross margin fell to 49.2% from 70.5%, impacted by currency, gold prices, and production costs

Company completed rights issue, raising about SEK 80 mln before costs

Outlook

SciBase did not provide specific guidance or forecasts for future quarters or the full year

Result Drivers

US AND SKIN BARRIER SALES - Co said Q1 sales growth was driven by a 79% increase in US skin cancer market sales and a 1,042% rise in skin barrier segment sales

ELECTRODE VOLUME - Electrode sales volume rose 70%, with repeat sales to existing customers up 73% including deliveries to Castle Biosciences

GROSS MARGIN PRESSURE - Gross margin fell due to negative currency effects, higher gold prices, deliveries for clinical studies, and production ramp-up investments

Company press release: ID:nWkr345fHq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 14.28 mln
Q1 EPS
-SEK 0.03
Q1 Net Income
-SEK 24.49 mln
Q1 Gross Margin
49.20%


Analyst Coverage

Wall Street's median 12-month price target for SciBase Holding AB (publ) is SEK0.50, about 22.5% above its May 6 closing price of SEK0.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)